Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
about
Persistent androgen receptor addiction in castration-resistant prostate cancerDiscovery and characterization of olokizumabSiltuximab (CNTO 328): a promising option for human malignanciesTargeted immune therapy of ovarian cancerRepositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapyNanoways to overcome docetaxel resistance in prostate cancer.Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.Trial Watch: Immunostimulatory cytokines.Overcoming drug resistance and treating advanced prostate cancerAnti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Proinflammatory and Anti-Inflammatory Cytokines Mediated by NF-κB Factor as Prognostic Markers in Mammary Tumors.Obesity and prostate cancer: weighing the evidence.Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium.The role of IL-6 in the radiation response of prostate cancerCancer prevention and therapy through the modulation of the tumor microenvironment.Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissuesTargeting the tumor microenvironment: from understanding pathways to effective clinical trials.Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation.The immune system in the pathogenesis of ovarian cancer.The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Interleukins in glioblastoma pathophysiology: implications for therapy.B-lymphocyte lineage cells and the respiratory system.Cell mates: paracrine and stromal targets for prostate cancer therapy.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agentsProinflammatory cytokine interleukin-6 in prostate carcinogenesisFrom physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.Paraneoplastic thrombocytosis in gastrointestinal cancer.STAT3 regulated ARF expression suppresses prostate cancer metastasis.A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells.Type I IFN gene delivery suppresses regulatory T cells within tumors.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
P2860
Q26777163-6C8DBED3-AA17-4C5C-B368-E63D92AF5E46Q27682535-5FA87B4B-072F-4E73-9162-8DEB35C8A5F8Q28082572-11DEE881-6460-4433-AE0D-41EB6452702DQ28082828-A5774002-6276-4C6C-A586-1AA5E49318C8Q33866426-AA1B4AD0-271A-40F3-82A3-76A3CBFE93F9Q33909084-5947071F-6096-436D-B183-309E5731381CQ35475443-E3B8AA6F-6469-41F0-BC85-6F79D250A1B6Q35685245-4F854DB9-DFE8-4294-A42E-88901BB65581Q36057492-0F18232B-D0DB-4BFB-84BA-3B465445467BQ36328812-D09AD41D-67B5-4C20-9D5A-F7A9B5A0114AQ36356086-A6BB1F83-9831-489E-8443-695F98101C40Q36407003-E435F7AA-C35D-483B-A20B-A34401EFD5F5Q36632887-3B681E32-5BDC-4502-9A17-A888DEEF8BA0Q36685022-24DBFABD-D06B-4B79-AB30-F48D1F0AA343Q36746178-5026FDDA-8869-4749-82D6-2435B90F15D4Q37028843-632ACCA8-4233-467D-A11B-271BDDC7CF94Q37058267-ECBCCBAF-D98A-4BF5-B2B6-DCFC458DBCCEQ37239331-E757BA36-3311-49D1-8DD1-AD9BCC396500Q37274132-ED09E261-6D98-49EC-BB2D-8600A9963334Q37582274-DE619791-869D-4226-90E0-40B3A0478D1AQ37613407-C1A990EB-666A-4C02-A576-9C71F0B79E97Q37615017-82DF4218-E465-4898-BA48-805952C83113Q38051761-89692F0D-4FB8-4D26-90E6-73AC0C0EAF6DQ38094250-3E0F58AC-96AE-4064-BB77-856A4F1490B6Q38121792-14BFA505-F5AF-4FA2-A4F1-4DA25D3F4124Q38203779-E4BE7E28-795A-4B55-A376-CB0D8F59C7E3Q38204742-6F8C065A-F216-48DC-83B9-3A0A3CCA7255Q38265575-C7F87D44-3DBA-43EC-BEFE-6522C46EF5FDQ38336406-115CA087-92DB-4E8D-9584-A9D2F1105A3FQ38382090-576A8478-B4D7-47DC-9AF5-62E0D5653BB8Q38687571-19836F0B-DEBA-47E6-A940-0374E27608FFQ38715211-CE63EEA0-D01B-4854-8E5C-A83C01173696Q38730792-1027CE43-5E66-492F-96C0-63373AD7540EQ38823142-99109EFD-1A31-4123-A7C9-93BE090D0C54Q38850627-EB5F8302-312D-436B-A83D-F721F7EE6BFDQ38866860-6680E617-02F4-47B2-9303-9205CAFE6CB9Q38937281-0EA28C0B-8721-4E90-868A-CD0F7FACA863Q39000185-924EF483-D358-490E-81AA-CA5B6B30384FQ39020147-6340C618-A294-4D9E-85ED-CFC3042FFE02Q39164084-7D5B861C-3DA5-45AA-927C-A2AB8ECE8BE8
P2860
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Randomised phase II study of s ...... ion-resistant prostate cancer.
@en
Randomised phase II study of s ...... ion-resistant prostate cancer.
@nl
type
label
Randomised phase II study of s ...... ion-resistant prostate cancer.
@en
Randomised phase II study of s ...... ion-resistant prostate cancer.
@nl
prefLabel
Randomised phase II study of s ...... ion-resistant prostate cancer.
@en
Randomised phase II study of s ...... ion-resistant prostate cancer.
@nl
P2093
P1476
Randomised phase II study of s ...... ion-resistant prostate cancer.
@en
P2093
A Heidenreich
J S De Bono
J T Vermeulen
M Cornfeld
P356
10.1016/J.EJCA.2011.10.014
P577
2011-11-28T00:00:00Z